Abstract
Helicobacter pylori infection causes chronic active gastritis, ulcer disease, and gastric cancer. Current eradication regimens use a proton pump inhibitor (PPI) and two antibiotics. Triple therapy now has a success rate less than 80%, below the cutoff for efficacious eradication. Antibiotic resistance, inconsistent acid control by PPIs, and poor patient compliance contribute to the failure rate. H. pylori is a neutralophile that has developed special acid acclimation mechanisms to colonize its acidic gastric niche. Identifying the components of these mechanisms will provide novel bactericidal drug targets. Alternatively, better 24-hour acid control would increase the efficacy of antibiotics, leading to dual therapy with improved PPIs and amoxicillin. Studies of acid acclimation by H. pylori have identified several potential eradication targets including UreI, α-carbonic anhydrase, and a two-component system. Continuing improvement of PPIs has led to the development of at least three candidate drugs with improved 24-hour acid control.
Similar content being viewed by others
References and Recommended Reading
Blaser MJ: Helicobacter pylori and gastric diseases. BMJ 1998, 316:1507–1510.
Akre K, Signorello LB, Engstrand L, et al.: Risk for gastric cancer after antibiotic prophylaxis in patients undergoing hip replacement. Cancer Res 2000, 60:6376–6380.
Uemura N, Okamoto S, Yamamoto S, et al.: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001, 345:784–789.
Cover TL, Blaser MJ: Helicobacter pylori in health and disease. Gastroenterology 2009, 136:1863–1873.
Loffeld RJ, Werdmuller BF, Kuster JG, et al.: Colonization with cagA-positive Helicobacter pylori strains inversely associated with reflux esophagitis and Barrett’s esophagus. Digestion 2000, 62:95–99.
Malfertheiner P, Megraud F, O’Morain C, et al.: Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007, 56:772–781.
Megraud F: Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther 1997, 11(Suppl 1):43–53.
Penston JG, McColl KE: Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol 1997, 43:223–243.
Dore MP, Leandro G, Realdi G, et al.: Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000, 45:68–76.
Furuta T, Shirai N, Takashima M, et al.: Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001, 11:341–348.
Teyssen S, Chari ST, Scheid J, Singer MV: Effect of repeated boluses of intravenous omeprazole and primed infusions of ranitidine on 24-hour intragastric pH in healthy human subjects. Dig Dis Sci 1995, 40:247–255.
Schreiber S, Konradt M, Groll C, et al.: The spatial orientation of Helicobacter pylori in the gastric mucus. Proc Natl Acad Sci U S A 2004, 101:5024–5029.
Code CF: Defense mechanisms of the gastric mucosa. Scand J Gastroenterol Suppl 1981, 67:201–204.
Schade C, Flemstrom G, Holm L: Hydrogen ion concentration in the mucus layer on top of acid-stimulated and -inhibited rat gastric mucosa. Gastroenterology 1994, 107:180–188.
Baumgartner HK, Montrose MH: Regulated alkali secretion acts in tandem with unstirred layers to regulate mouse gastric surface pH. Gastroenterology 2004, 126:774–783.
Henriksnas J, Phillipson M, Storm M, et al.: Impaired mucusbicarbonate barrier in Helicobacter pylori-infected mice. Am J Physiol Gastrointest Liver Physiol 2006, 291:G396–G403.
Scott DR, Marcus EA, Wen Y, et al.: Gene expression in vivo shows that Helicobacter pylori colonizes an acidic niche on the gastric surface. Proc Natl Acad Sci U S A 2007, 104:7235–7240.
Mitchell P: Chemiosmotic coupling in oxidative and photosynthetic phosphorylation. Biol Rev Camb Philos Soc 1966, 41:445–502.
Padan E, Zilberstein D, Schuldiner S: pH homeostasis in bacteria. Biochim Biophys Acta 1981, 650:151–166.
Foster JW: Escherichia coli acid resistance: tales of an amateur acidophile. Nat Rev Microbiol 2004, 2:898–907.
Wen Y, Marcus EA, Matrubutham U, et al.: Acid-adaptive genes of Helicobacter pylori. Infect Immun 2003, 71:5921–5939.
Mobley HL, Island MD, Hausinger RP: Molecular biology of microbial ureases. Microbiol Rev 1995, 59:451–480.
Eaton KA, Brooks CL, Morgan DR, Krakowka S: Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets. Infect Immun 1991, 59:2470–2475.
Cussac V, Ferrero RL, Labigne A: Expression of Helicobacter pylori urease genes in Escherichia coli grown under nitrogen-limiting conditions. J Bacteriol 1992, 174:2466–2473.
Voland P, Weeks DL, Marcus EA, et al.: Interactions among the seven Helicobacter pylori proteins encoded by the urease gene cluster. Am J Physiol Gastrointest Liver Physiol 2003, 284:G96–G106.
Nolan KJ, McGee DJ, Mitchell HM, et al.: In vivo behavior of a Helicobacter pylori SS1 nixA mutant with reduced urease activity. Infect Immun 2002, 70:685–691.
Olson JW, Mehta NS, Maier RJ: Requirement of nickel metabolism proteins HypA and HypB for full activity of both hydrogenase and urease in Helicobacter pylori. Mol Microbiol 2001, 39:176–182.
Scott DR, Marcus EA, Weeks DL, et al.: Expression of the Helicobacter pylori ureI gene is required for acidic pH activation of cytoplasmic urease. Infect Immun 2000, 68:470–477.
Mollenhauer-Rektorschek M, Hanauer G, Sachs G, Melchers K: Expression of UreI is required for intragastric transit and colonization of gerbil gastric mucosa by Helicobacter pylori. Res Microbiol 2002, 153:659–666.
Skouloubris S, Thiberge JM, Labigne A, De Reuse H: The Helicobacter pylori UreI protein is not involved in urease activity but is essential for bacterial survival in vivo. Infect Immun 1998, 66:4517–4521.
Weeks DL, Gushansky G, Scott DR, Sachs G: Mechanism of proton gating of a urea channel. J Biol Chem 2004, 279:9944–9950.
You G, Smith CP, Kanai Y, et al.: Cloning and characterization of the vasopressin-regulated urea transporter. Nature 1993, 365:844–847.
Ang S, Lee CZ, Peck K, et al.: Acid-induced gene expression in Helicobacter pylori: study in genomic scale by microarray. Infect Immun 2001, 69:1679–1686.
Bury-Mone S, Thiberge JM, Contreras M, et al.: Responsiveness to acidity via metal ion regulators mediates virulence in the gastric pathogen Helicobacter pylori. Mol Microbiol 2004, 53:623–638.
Merrell DS, Goodrich ML, Otto G, et al.: pH-regulated gene expression of the gastric pathogen Helicobacter pylori. Infect Immun 2003, 71:3529–3539.
Mehta N, Olson JW, Maier RJ: Characterization of Helicobacter pylori nickel metabolism accessory proteins needed for maturation of both urease and hydrogenase. J Bacteriol 2003, 185:726–734.
Marcus EA, Moshfegh AP, Sachs G, Scott DR: The periplasmic alpha-carbonic anhydrase activity of Helicobacter pylori is essential for acid acclimation. J Bacteriol 2005, 187:729–738.
Bury-Mone S, Mendz GL, Ball GE, et al.: Roles of alpha and beta carbonic anhydrases of Helicobacter pylori in the urease-dependent response to acidity and in colonization of the murine gastric mucosa. Infect Immun 2008, 76:497–509.
Beier D, Frank R: Molecular characterization of two-component systems of Helicobacter pylori. J Bacteriol 2000, 182:2068–2076.
Wen Y, Feng J, Scott DR, et al.: The HP0165-HP0166 two-component system (ArsRS) regulates acid-induced expression of HP1186 α-carbonic anhydrase in Helicobacter pylori by activating the pH-dependent promoter. J Bacteriol 2007, 189:2426–2434.
Niehus E, Gressmann H, Ye F, et al.: Genome-wide analysis of transcriptional hierarchy and feedback regulation in the flagellar system of Helicobacter pylori. Mol Microbiol 2004, 52:947–961.
Pflock M, Finsterer N, Joseph B, et al.: Characterization of the ArsRS regulon of Helicobacter pylori, involved in acid adaptation. J Bacteriol 2006, 188:3449–3462.
Ottemann KM, Lowenthal AC: Helicobacter pylori uses motility for initial colonization and to attain robust infection. Infect Immun 2002, 70:1984–1990.
Pflock M, Muller S, Beier D: The CrdRS (HP1365-HP1364) two-component system is not involved in pH-responsive gene regulation in the Helicobacter pylori strains 26695 and G27. J Bacteriol 2007, 54:320–324.
Hong W, Sano K, Morimatsu S, et al.: Medium pH-dependent redistribution of the urease of Helicobacter pylori. J Med Microbiol 2003, 52:211–216.
Metz DC, Vakily M, Dixit T, Mulford D: Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther 2009, 29:928–937.
Galmiche JP, Bruley Des Varannes S, Ducrotte P, et al.: Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther 2004, 19:655–662.
Puscas I, Paun R, Ursea N, et al.: Carbonic anhydrase inhibitors in the treatment of gastric and duodenal ulcers [in French, author’s transl]. Arch Fr Mal App Dig 1976, 65:577–583.
Marshall BJ, Warren JR: Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984, 1:1311–1315.
Scott DR, Marcus EA, Weeks DL, Sachs G: Mechanisms of acid resistance due to the urease system of Helicobacter pylori. Gastroenterology 2002, 123:187–195.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sachs, G., Wen, Y. & Scott, D.R. Gastric infection by Helicobacter pylori . Curr Gastroenterol Rep 11, 455–461 (2009). https://doi.org/10.1007/s11894-009-0070-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11894-009-0070-y